Kolon Life Science Inc. (KOSDAQ: 102940)
South Korea
· Delayed Price · Currency is KRW 18,510
+160 (0.87%)
Sep 11, 2024, 11:03 AM KST
Kolon Life Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -84,287 | -30,726 | 2,133 | -1,375 | -43,195 | -92,323 | Upgrade
|
| Depreciation & Amortization | 8,448 | 8,831 | 9,467 | 11,299 | 13,030 | 14,039 | Upgrade
|
| Loss (Gain) From Sale of Assets | 7.01 | -3,477 | 760.83 | -72.29 | -3,571 | 131.63 | Upgrade
|
| Asset Writedown & Restructuring Costs | 3,138 | 4,350 | 2,822 | 4,327 | 1,090 | 1,875 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | 14.53 | 5.18 | -11.07 | - | -500 | Upgrade
|
| Provision & Write-off of Bad Debts | -0 | 78.01 | - | -375.82 | 115.8 | 260.01 | Upgrade
|
| Other Operating Activities | 60,693 | 9,444 | -3,413 | 2,146 | 16,981 | 68,260 | Upgrade
|
| Change in Accounts Receivable | -9,799 | 4,713 | -10,666 | 2,502 | 6,268 | -5,984 | Upgrade
|
| Change in Inventory | -84.91 | -2,126 | -23,842 | -3,810 | -3,552 | -2,722 | Upgrade
|
| Change in Accounts Payable | 1,096 | -5,448 | 3,420 | 1,952 | 1,162 | 477.9 | Upgrade
|
| Change in Unearned Revenue | - | - | -299 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -6,115 | -7,645 | -3,125 | -32,771 | 4,366 | -3,695 | Upgrade
|
| Operating Cash Flow | -29,777 | -24,866 | -20,854 | -16,187 | -7,307 | -20,181 | Upgrade
|
| Capital Expenditures | -9,828 | -10,144 | -6,305 | -4,413 | -2,743 | -30,779 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 20.14 | 168 | 3.64 | 563.41 | Upgrade
|
| Sale (Purchase) of Intangibles | -461.3 | 3,407 | -2.2 | -43 | - | 2,365 | Upgrade
|
| Investment in Securities | - | -14.53 | 360 | 2,224 | 13,787 | 8,591 | Upgrade
|
| Other Investing Activities | -60.83 | -274.48 | -9.13 | -190.45 | 7,990 | -354.29 | Upgrade
|
| Investing Cash Flow | -10,350 | -7,026 | -5,937 | -2,255 | 19,037 | -19,613 | Upgrade
|
| Short-Term Debt Issued | - | 128,212 | 101,092 | 121,103 | 96,073 | 731,490 | Upgrade
|
| Long-Term Debt Issued | - | 9,975 | - | - | - | - | Upgrade
|
| Total Debt Issued | 113,465 | 138,187 | 101,092 | 121,103 | 96,073 | 731,490 | Upgrade
|
| Short-Term Debt Repaid | - | -100,437 | -90,238 | -123,741 | -87,923 | -710,484 | Upgrade
|
| Long-Term Debt Repaid | - | -4,861 | -6,049 | -5,978 | -10,529 | -7,992 | Upgrade
|
| Total Debt Repaid | -94,060 | -105,298 | -96,287 | -129,718 | -98,451 | -718,476 | Upgrade
|
| Net Debt Issued (Repaid) | 19,405 | 32,889 | 4,804 | -8,615 | -2,379 | 13,014 | Upgrade
|
| Issuance of Common Stock | 20,000 | - | - | - | - | - | Upgrade
|
| Other Financing Activities | -12.09 | -0 | 653.6 | 39,564 | - | - | Upgrade
|
| Financing Cash Flow | 39,393 | 32,889 | 5,458 | 30,949 | -2,379 | 13,014 | Upgrade
|
| Foreign Exchange Rate Adjustments | 251.01 | 192.24 | -96.34 | 292.46 | -264.03 | 22.29 | Upgrade
|
| Net Cash Flow | -482.56 | 1,190 | -21,429 | 12,799 | 9,087 | -26,758 | Upgrade
|
| Free Cash Flow | -39,604 | -35,009 | -27,159 | -20,600 | -10,050 | -50,960 | Upgrade
|
| Free Cash Flow Margin | -28.23% | -28.09% | -16.81% | -12.45% | -7.77% | -34.31% | Upgrade
|
| Free Cash Flow Per Share | -3462.04 | -3067.66 | -2149.14 | -1807.01 | -881.60 | -4469.86 | Upgrade
|
| Cash Interest Paid | 7,337 | 5,116 | 2,992 | 2,459 | 2,039 | 2,396 | Upgrade
|
| Cash Income Tax Paid | - | 112.55 | 0.82 | -32.94 | -0.14 | -124.31 | Upgrade
|
| Levered Free Cash Flow | 21,512 | -15,476 | -26,124 | -25,821 | -12,554 | - | Upgrade
|
| Unlevered Free Cash Flow | 25,913 | -11,815 | -23,798 | -22,063 | -9,105 | - | Upgrade
|
| Change in Net Working Capital | -42,631 | -1,151 | 28,609 | 31,562 | 3,245 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.